This article is more than 5 years old. Information may no longer be current.
Bacterin releases new hammertoe offering
Click Here to Manage Email Alerts
Bacterin International Holdings recently announced the release of ArthroFuse, an allograft offering to treat hammertoe deformities.
The implant is designed to evolve during the healing process into the patient’s own bone structure, eliminating the need for permanent implants and externally communicating pins in the foot, according to a company press release.
A patent remains pending on ArthoFuse.
“We are excited to announce the launch of ArthroFuse, the newest addition to our regenerative biologics portfolio,” Gregory Juda, PhD, chief scientific officer for Bacterin, said in the release. “We developed this product in response to the needs of our surgeon end users to allow them to successfully treat this commonly painful pathology.”
Reference: www.bacterin.com.